Migraine disease exists on a spectrum, presenting patients with different frequencies of attacks, whose duration and effect vary from person to person. Treating migraine disease is, therefore, an exercise in mixing and matching, trial and error.
Migraine at Work, a project of the Headache and Migraine Policy Forum, has launched a new website to support employers and employees with the tools they need to build happier, healthier and more productive workplaces. Whether you’re looking to initiate a positive conversation with your employer or simply learn about effective strategies for managing your disease at work, this website is a great place to start.
Amgen is a founding sponsor of Migraine at Work.
CHICAGO — The AMA strongly backs the comprehensive, common-sense proposals the Interagency Pain Task Force discussed today, sending a clear signal to the physician community that policy makers understand the treatment required for patients in pain.
Policymakers, providers and patients all feel the impact of The Institute for Clinical and Economic Review, whose ubiquitous cost-effectiveness reports can determine patients’ access to medicine. But could these stakeholders and the public find real answers to basic questions – like “What is ICER?” and “Who controls ICER?”
Click below to read the report.
Click below to view graphic.
It might mean swapping out fluorescent light bulbs, implementing a flexible work schedule, or providing a dark room where staff can recover from migraine attacks.
For years, migraine disease stole time, personal goals, career plans and even Jaime Sanders’ ideal of motherhood. But her condition no longer manages her, she manages it—and she advocates so migraine disease patients can access the innovative medications they need.
Which patients should get the new calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine prevention -- and what will payers agree to?
During the past year, there’s been a clear shift in how patient organizations are engaging with the Institute for Clinical and Economic Review (ICER) and its value assessments of new, and often first-of-their-kind, medicines.